In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

Feb 2

1 min read

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy patients. Using rats, the researchers determined that PRDX2 helped reduce inflammation, suggesting that it has a protective role and might have therapeutic use.

Read the Scientific Reports article

Recent Posts

Using antithrombotics in children with PH

A study used US registry data and a survey to explore the usage of antithrombotic therapy in children with pulmonary hypertension (PH). Antithrombotic therapy is used infrequently in pediatric PH and

Selexipag side effects are associated with hemodynamic responses

A Japanese study examined whether selexipag side effects were associated with hemodynamic responses and found that headaches might be associated with treatment responsiveness and a better prognosis th

Patient and Clinician Views on Shared Decision-Making

Preference for shared decision-making was nearly universal among patients and clinicians. However, priorities differed significantly. Patients more frequently emphasized quality of life (81% vs. 54%)

Comments